CSIMarket
 
Personalis Inc   (NASDAQ: PSNL)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $17.0700 $0.29 1.728%
Day's High: $17.375600814819336 Week Perf: -0.06 %
Day's Low: $ 16.86 30 Day Perf: 44.05 %
Volume (M): 1,017,893 52 Wk High: $ 18.89
Volume (M$): $ 0 52 Wk Avg: $9.20
Open: $17.13 52 Wk Low: $4.67



 Market Capitalization (Millions $) 1,800
 Shares Outstanding (Millions) 105
 Employees 260
 Revenues (TTM) (Millions $) 70
 Net Income (TTM) (Millions $) -107
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 5

Business Description


Personalis Inc is a biotechnology company based in California, United States. The company specializes in advanced genomics and precision medicine, providing genomic sequencing and analysis solutions to support the development of personalized therapies and precision diagnostics.

Personalis uses its proprietary ACE (Accuracy and Content Enhanced) technology to generate accurate and comprehensive genomic data, which can help researchers and healthcare professionals in the discovery and development of therapies. The company's technology can analyze complex genomes, including cancer genomes, and provides insights into disease biology, immune response, and drug sensitivity.

Personalis also offers a range of services, including cancer genomics, clinical genetics, and population genomics. Their services help researchers and clinicians understand the individual variations in genome sequences and interpret their impact on health conditions and diseases.

The company has partnerships with pharmaceutical and biotech companies, academic institutions, and research organizations to collaborate on various genomics research projects. It has a strong focus on translating genomic data into actionable information that can improve patient care and outcomes.

Overall, Personalis Inc plays a crucial role in advancing precision medicine by leveraging genomic analysis to provide personalized insights into disease biology and treatment options.


   Company Address: 6600 Dumbarton Circle Fremont 94555 CA
   Company Phone Number: 752-1300   Stock Exchange / Ticker: NASDAQ PSNL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDNA   -2.66%    
FLGT   -2.56%    
FTRE   -0.05%    
GH   -2.75%    
NTRA   -3.9%    
VCYT   -0.79%    
• View Complete Report
   



Business Update

Personalis Medicare Coverage Sparks Hope Amidst Competitive Challenges in Precision Oncology

Published Mon, Nov 10 2025 2:49 PM UTC

In a landmark development for breast cancer patients and the realm of precision oncology, Personalis, Inc. (Nasdaq: PSNL) has announced Medicare coverage for its ultrasensitive NeXT Personal test, designed for monitoring cancer recurrence. This announcement represents a significant advancement in cancer surveillance, particularly for Medicare beneficiaries diagnosed with sta...

Business Update

Innovative Clinical Trial Paves the Way for ctDNA-Guided Treatment in Breast Cancer

Published Thu, Sep 11 2025 3:48 AM UTC

In a pioneering leap for precision oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics, has announced a promising collaboration with a renowned team from Yale Cancer Center. Together, they are embarking on an ambitious clinical trial aimed at demonstrating the transformative potential of circulating tumor DNA (ctDNA) in guiding breast cancer treatment de...

Business Update

Evolving Lung Cancer Treatment Personalis Unveils Landmark Findings in Neoadjuvant Therapy

Published Thu, Sep 4 2025 3:10 AM UTC

In a significant advancement for oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic solutions, has unveiled pivotal new data from a landmark phase 3 clinical trial, NeoADAURA, in collaboration with AstraZeneca. This groundbreaking research identifies Personalis’ NeXT Personal molecular residual disease (MRD) test as a powerful tool in predicting outcom...

Business Update

Personalis and Tempus Expand Collaboration to Introduce Advanced Cancer Recurrence Testing for Colorectal Cancer Pa...

Published Thu, Jul 10 2025 6:02 PM UTC

Personalis and Tempus Expand Collaboration to Introduce Advanced Cancer Recurrence Testing for Colorectal Cancer PatientsIn a significant advancement for oncology diagnostics, Personalis, Inc. (Nasdaq: PSNL) has announced the expansion of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM). This partnership now includes the development of cutting-edge diagnostic ...

Business Update

Empowering Precision Medicine Personalis Strengthens Ties with Merck and Moderna Amid Strategic Surge,

Published Thu, Dec 19 2024 4:47 PM UTC

Investments and Collaborations Propel Personalis Inc. into a New Strategic Era FREMONT, Calif. In a significant advance towards a burgeoning future, Personalis, Inc. (NASDAQ: PSNL), a key player in the biotechnology landscape, has announced pivotal agreements with pharmaceutical titans Merck and Moderna. These collaborations mark not just an infusion of capital and confide...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 25.83
Price to Sales (Expected) -
Price to Book 7.65
PEG (TTM) -

Financial Strength Current
Quick Ratio 6
Working Capital Ratio 6.53
Leverage Ratio (MRQ) 0.33
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.1 $
Revenues (TTM) 0.66 $
Cash Flow (TTM) 0.19 $
Cash 2.64 $
Book Value 2.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 267,958
Net Income per Employee (TTM) -412,227
Receivable Turnover Ratio (TTM) 4.75
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.21

Profitability Ratios Current
Gross Margin (MRQ) 21.21 %
Operating Margin (MRQ) -150.25 %
Net Margin (MRQ) -141.71 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Personalis Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.